Inside J&J’s New Initiative to ‘Intercept’ Diseases

The pharmaceutical industry typically develops new drugs to help manage diseases.  But a new project inside Johnson & Johnson posits a different model: what if you could identify people at risk of developing a disease, and create products to stave it off? Ben Wiegand, head of the Disease Interception Accelerator, explains what they’re up to.